Resistance emerges to second-generation antiandrogens in prostate cancer.
Resistance emerges to second-generation antiandrogens in prostate cancer.
复制标题
DOI：
10.1158/2159-8290.cd-13-0405
复制
发表时间：
2013-09
期刊：
影响因子：
28.2
通讯作者：
Yegnasubramanian S
中科院分区：
文献类型：
--
作者：
Nelson WG;Yegnasubramanian S
在长期暴露于苯扎鲁胺或ARN-509的前列腺癌细胞中，突变的雄激素受体F876L-AR的出现促进了从拮抗剂到激动剂受体功能的转换，破坏了这些第二代抗雄激素药物的潜在长期有效性。
The appearance of a mutant androgen receptor, F876L-AR, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long term effectiveness of these second generation anti-androgen drugs.